These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22302717)

  • 1. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.
    Leidner RS; Ravi L; Leahy P; Chen Y; Bednarchik B; Streppel M; Canto M; Wang JS; Maitra A; Willis J; Markowitz SD; Barnholtz-Sloan J; Adams MD; Chak A; Guda K
    Genes Chromosomes Cancer; 2012 May; 51(5):473-9. PubMed ID: 22302717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the current understanding and clinical utility of miRNAs in esophageal cancer.
    Sakai NS; Samia-Aly E; Barbera M; Fitzgerald RC
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):512-21. PubMed ID: 24013023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium.
    Drahos J; Schwameis K; Orzolek LD; Hao H; Birner P; Taylor PR; Pfeiffer RM; Schoppmann SF; Cook MB
    Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):429-37. PubMed ID: 26604271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the unique microRNA signature in human esophageal adenocarcinoma.
    Saad R; Chen Z; Zhu S; Jia P; Zhao Z; Washington MK; Belkhiri A; El-Rifai W
    PLoS One; 2013; 8(5):e64463. PubMed ID: 23724052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.
    Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ
    World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
    Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
    Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
    Maru DM; Singh RR; Hannah C; Albarracin CT; Li YX; Abraham R; Romans AM; Yao H; Luthra MG; Anandasabapathy S; Swisher SG; Hofstetter WL; Rashid A; Luthra R
    Am J Pathol; 2009 May; 174(5):1940-8. PubMed ID: 19342367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
    Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
    Streppel MM; Pai S; Campbell NR; Hu C; Yabuuchi S; Canto MI; Wang JS; Montgomery EA; Maitra A
    Clin Cancer Res; 2013 Aug; 19(15):4067-78. PubMed ID: 23757351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer.
    Garman KS; Owzar K; Hauser ER; Westfall K; Anderson BR; Souza RF; Diehl AM; Provenzale D; Shaheen NJ
    Dig Dis Sci; 2013 Nov; 58(11):3178-88. PubMed ID: 23925817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
    Smith CM; Watson DI; Leong MP; Mayne GC; Michael MZ; Wijnhoven BP; Hussey DJ
    World J Gastroenterol; 2011 Feb; 17(8):1036-44. PubMed ID: 21448356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
    Beilstein M; Silberg D
    Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.